Cargando…

The Lung Microbiome in Idiopathic Pulmonary Fibrosis: A Promising Approach for Targeted Therapies

This review focuses on the role of the lung microbiome in idiopathic pulmonary fibrosis. Although historically considered sterile, bacterial communities have now been well documented in lungs both in healthy and pathological conditions. Studies in idiopathic pulmonary fibrosis (IPF) suggest that inc...

Descripción completa

Detalles Bibliográficos
Autores principales: Fastrès, Aline, Felice, Florence, Roels, Elodie, Moermans, Catherine, Corhay, Jean-Louis, Bureau, Fabrice, Louis, Renaud, Clercx, Cécile, Guiot, Julien
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5751336/
https://www.ncbi.nlm.nih.gov/pubmed/29258183
http://dx.doi.org/10.3390/ijms18122735
_version_ 1783289928008859648
author Fastrès, Aline
Felice, Florence
Roels, Elodie
Moermans, Catherine
Corhay, Jean-Louis
Bureau, Fabrice
Louis, Renaud
Clercx, Cécile
Guiot, Julien
author_facet Fastrès, Aline
Felice, Florence
Roels, Elodie
Moermans, Catherine
Corhay, Jean-Louis
Bureau, Fabrice
Louis, Renaud
Clercx, Cécile
Guiot, Julien
author_sort Fastrès, Aline
collection PubMed
description This review focuses on the role of the lung microbiome in idiopathic pulmonary fibrosis. Although historically considered sterile, bacterial communities have now been well documented in lungs both in healthy and pathological conditions. Studies in idiopathic pulmonary fibrosis (IPF) suggest that increased bacterial burden and/or abundance of potentially pathogenic bacteria may drive disease progression, acute exacerbations, and mortality. More recent work has highlighted the interaction between the lung microbiome and the innate immune system in IPF, strengthening the argument for the role of both host and environment interaction in disease pathogenesis. Existing published data suggesting that the lung microbiome may represent a therapeutic target, via antibiotic administration, immunization against pathogenic organisms, or treatment directed at gastroesophageal reflux. Taken altogether, published literature suggests that the lung microbiome might serve in the future as a prognostic biomarker, a therapeutic target, and/or provide an explanation for disease pathogenesis in IPF.
format Online
Article
Text
id pubmed-5751336
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-57513362018-01-08 The Lung Microbiome in Idiopathic Pulmonary Fibrosis: A Promising Approach for Targeted Therapies Fastrès, Aline Felice, Florence Roels, Elodie Moermans, Catherine Corhay, Jean-Louis Bureau, Fabrice Louis, Renaud Clercx, Cécile Guiot, Julien Int J Mol Sci Review This review focuses on the role of the lung microbiome in idiopathic pulmonary fibrosis. Although historically considered sterile, bacterial communities have now been well documented in lungs both in healthy and pathological conditions. Studies in idiopathic pulmonary fibrosis (IPF) suggest that increased bacterial burden and/or abundance of potentially pathogenic bacteria may drive disease progression, acute exacerbations, and mortality. More recent work has highlighted the interaction between the lung microbiome and the innate immune system in IPF, strengthening the argument for the role of both host and environment interaction in disease pathogenesis. Existing published data suggesting that the lung microbiome may represent a therapeutic target, via antibiotic administration, immunization against pathogenic organisms, or treatment directed at gastroesophageal reflux. Taken altogether, published literature suggests that the lung microbiome might serve in the future as a prognostic biomarker, a therapeutic target, and/or provide an explanation for disease pathogenesis in IPF. MDPI 2017-12-16 /pmc/articles/PMC5751336/ /pubmed/29258183 http://dx.doi.org/10.3390/ijms18122735 Text en © 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Fastrès, Aline
Felice, Florence
Roels, Elodie
Moermans, Catherine
Corhay, Jean-Louis
Bureau, Fabrice
Louis, Renaud
Clercx, Cécile
Guiot, Julien
The Lung Microbiome in Idiopathic Pulmonary Fibrosis: A Promising Approach for Targeted Therapies
title The Lung Microbiome in Idiopathic Pulmonary Fibrosis: A Promising Approach for Targeted Therapies
title_full The Lung Microbiome in Idiopathic Pulmonary Fibrosis: A Promising Approach for Targeted Therapies
title_fullStr The Lung Microbiome in Idiopathic Pulmonary Fibrosis: A Promising Approach for Targeted Therapies
title_full_unstemmed The Lung Microbiome in Idiopathic Pulmonary Fibrosis: A Promising Approach for Targeted Therapies
title_short The Lung Microbiome in Idiopathic Pulmonary Fibrosis: A Promising Approach for Targeted Therapies
title_sort lung microbiome in idiopathic pulmonary fibrosis: a promising approach for targeted therapies
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5751336/
https://www.ncbi.nlm.nih.gov/pubmed/29258183
http://dx.doi.org/10.3390/ijms18122735
work_keys_str_mv AT fastresaline thelungmicrobiomeinidiopathicpulmonaryfibrosisapromisingapproachfortargetedtherapies
AT feliceflorence thelungmicrobiomeinidiopathicpulmonaryfibrosisapromisingapproachfortargetedtherapies
AT roelselodie thelungmicrobiomeinidiopathicpulmonaryfibrosisapromisingapproachfortargetedtherapies
AT moermanscatherine thelungmicrobiomeinidiopathicpulmonaryfibrosisapromisingapproachfortargetedtherapies
AT corhayjeanlouis thelungmicrobiomeinidiopathicpulmonaryfibrosisapromisingapproachfortargetedtherapies
AT bureaufabrice thelungmicrobiomeinidiopathicpulmonaryfibrosisapromisingapproachfortargetedtherapies
AT louisrenaud thelungmicrobiomeinidiopathicpulmonaryfibrosisapromisingapproachfortargetedtherapies
AT clercxcecile thelungmicrobiomeinidiopathicpulmonaryfibrosisapromisingapproachfortargetedtherapies
AT guiotjulien thelungmicrobiomeinidiopathicpulmonaryfibrosisapromisingapproachfortargetedtherapies
AT fastresaline lungmicrobiomeinidiopathicpulmonaryfibrosisapromisingapproachfortargetedtherapies
AT feliceflorence lungmicrobiomeinidiopathicpulmonaryfibrosisapromisingapproachfortargetedtherapies
AT roelselodie lungmicrobiomeinidiopathicpulmonaryfibrosisapromisingapproachfortargetedtherapies
AT moermanscatherine lungmicrobiomeinidiopathicpulmonaryfibrosisapromisingapproachfortargetedtherapies
AT corhayjeanlouis lungmicrobiomeinidiopathicpulmonaryfibrosisapromisingapproachfortargetedtherapies
AT bureaufabrice lungmicrobiomeinidiopathicpulmonaryfibrosisapromisingapproachfortargetedtherapies
AT louisrenaud lungmicrobiomeinidiopathicpulmonaryfibrosisapromisingapproachfortargetedtherapies
AT clercxcecile lungmicrobiomeinidiopathicpulmonaryfibrosisapromisingapproachfortargetedtherapies
AT guiotjulien lungmicrobiomeinidiopathicpulmonaryfibrosisapromisingapproachfortargetedtherapies